Rocket Pharmaceuticals Inc

  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing


$16.52 ▼-0.9%

Extented Hours




16.23 - 17.19


7.57 - 23.48

Join Discuss about RCKT with like-minded investors

@DarkPoolAlgo #Dark Pool Charts

Tuesday, August 10, 2021 Futures Up/Down % Last Dow -19.00 0.05% 34,979 S&P 500 -0.25 0.02% 4,425 Nasdaq 17.50 0.12% 15,142 Stock markets are looking quiet again, as major averages have been holding near record highs but struggling for direction to start the week. Stronger economic data last Friday on the form of non-farm payrolls and declining unemployment helped boost sentiment about the economy, overshadowing any uncertainty over what impact the fast-spreading delta virus variant will have on the economy and comments from Federal Reserve officials about scaling back support. In Asian markets, The Nikkei Index gained 68 points to settle at 27,888, the Shanghai Index jumped 35 points to 3,529, and the Hang Seng Index gained 322 points (1.23%) to close at 26,605. In Europe, the German DAX is up around 25 points to 15,770, while the FTSE 100 is down a few points at 7,125. Today a fairly busy day of economic data, but all eyes fixed on the inflation reports coming up tomorrow (CPI) and on Thursday (PP), to see if the four-month spike in prices is indeed transitory as the Fed has pledged or if it is something more troubling for consumers down the line. Earnings season has begun to slow, with nearly 450 S&P companies having reported this quarter, with only some big retailers (WMT, TGT, HD, LOW) remaining. Trading ranges have remained in tight ranges of late, as summer doldrums have kicked in early. Market Closing Prices Yesterday The S&P 500 Index slipped -4.17 points, or 0.09%, to 4,432.35 The Dow Jones Industrial Average fell -106.66 points, or 0.30%, to 35,101.85 The Nasdaq Composite gained 24.42 points, or 0.16%, to 14,860.18 The Russell 2000 Index declined -12.95 points, or 0.58% to 2,234.81 Events Calendar for Today 6:00 AM ET NFIB Small Business Optimism for July 7:45 AM ET ICSC Weekly Retail Sales 8:30 AM ET Non-farm Productivity, prelim-Q2 8:30 AM ET Unit Labor Costs, prelim-Q2 8:55 AM ET Johnson/Redbook Weekly Sales 1:00 PM ET U.S. to sell $58 bln in 3-year notes 4:30 PM ET API Weekly Inventory Data Earnings Calendar: Earnings Before the Open: BSY, BTAI, CSPR, FULC, GTIM, IIVI, JBI, KPLT, LAND, LODE, MRNSD, MTNB, NAUT, OWL, SMID, SYY, TDG, TDW, VITL, VPG, VSH, VTNR Earnings After the Close: AIRG, AVGR, BVS, CHK, CLSD, COIN, COKE, CSSE, CURI, DAR, DOCS, EPAY, FTEK, GO, HCKT, HYRE, JAMF, KODK, KTCC, LPRO, LRN, MCFE, MEG, NARI, NVEE, OPFI, PANL, PAY, PAYS, PLBY, POSH, PUBM, SFT, SIEN, SMCI, TASK, TDUP, U, UPST, VEC, WW, ZETA Other Key Events: BTIG Biotechnology Conference 2021 (virtual), 8/9-8/10 Canaccord Genuity 41st Annual Growth Conference (virtual), 8/10-8/12 Cowen Annual Communications Infrastructure Hybrid Summit, 8/9-8/12 Cowen 9th Annual Internet & Media Bus Tour (virtual), 8/9-8/13 KeyBanc Capital Markets Technology Leadership Virtual Forum, 8/9-8/12 Oppenheimer 24th Annual Technology, Internet & Comm Conference (virtual), 8/10-8/12 Piper Biotech Virtual Tour, 8/10-8/12 Susquehanna 2021 Energy, Industrials & Airlines Conference (virtual), 8/10-8/11 UBS Financial Services Conference (virtual), 8/10-8/12 Wells Fargo 6th Annual FinTech & Technology Services Forum (virtual), 8/10-8/11 Macro Up/Down Last Nymex 1.05 67.51 Brent 0.84 69.88 Gold -1.00 1,728.90 EUR/USD -0.0018 1.1719 JPY/USD 0.24 110.53 10-Year Note +0.002 1.319% World News The NFIB Small Business Optimism Index was 99.7 vs. 103.3 consensus, and down from 102.5 in June. Germany Aug ZEW Sentiment4, well below the 56.7 consensus; conditions 29.3 vs 30.0 consensus; expectations decline for third time in a row; concerns over 4th wave of COVID affecting German economy in the Autumn Sector News Breakdown Consumer AMC Entertainment ($AMC) Q2 adj EPS loss (-$0.71) vs. est. loss (-$0.93); Q2 revs $444.7M vs. est. $381.28M; currently has liquidity availability of more than $2.0 billion; said welcomed more than 22 million guests back to theatres during Q2; said as of June 30, 2021, operated 593 domestic theatres & 335 international theatres Calloway ($ELY) 2Q adj EPS $0.36 vs est. $0.01 on revs $914Mm vs est. $753.1Mm; guides 3Q revs $775-790Mm vs est. $763Mm, sees 3Q adj EBITDA $51-58Mm vs est. $77.3Mm; guides FY revs $3.025-3.055B vs est. $2.84B, sees FY adj EBITDA $345-360Mm vs est. $295.3Mm CarLotz ($LOTZ) 2Q EPS ($0.06) vs est. ($0.20) on revs $50.8Mm vs est. $48.1Mm; withdraws previous FY21 outlook due to channel constraints Chegg Inc. ($CHGG) 2Q adj EPS $0.43 vs est. $0.37 on revs $198.5Mm vs est. $190.1Mm; guides 3Q revs $170-175Mm vs est. $173Mm; guides FY21 revs $805-815Mm vs est. $797.8Mm, sees FY adj EBITDA $295-300Mm vs est. $278.6Mm DoorDash ($DOOR) 2Q adj EPS $2.23 vs est. $2.09 on revs $662Mm vs est. $635.2Mm; guides FY sales +17-20% vs est. +14.5%, sees FY adj EPS $8.00-8.60 vs est. $8.50 Inter Parfums ($IPAR) 2Q EPS $0.71 vs est. $0.43 on revs $207.6Mm vs est. $207.6m; continues to see FY revs approx $750Mm vs est. $758.1Mm, EPS $1.95 vs est. $1.93 Nautilus ($NLS) Q1 EPS $0.43 vs. est. $0.30; Q1 revs $185M vs. est. $169.05M; said Q1 retail grew sales by 91% or 107% excluding Octane, delivering record net sales of $120 million, while Direct grew by 26%; sees Q2 revs $145M-$155M vs. est. $153.05M Original BARK ($BARK) 1Q adj EPS ($0.09) vs est. ($0.06) on revs $117.6Mm vs est. $116.8Mm; guides 2Q revs $122Mm vs est. $120.3Mm; reaffirms FY guide, sees FY revs $516Mm vs est. $516.5Mm Plant Fitness ($PLNT) Q2 adj EPS $0.21 vs. est. $0.23; Q2 revs $137.3M vs. est. $127.2M; ends second quarter with total membership of more than 14.8M and over 98% of stores open globally; Q2 adj EBITDA increased $64.8M to $55.6M from a loss of $9.3M in the prior year period; sees FY21 adj EPS $0.65-$0.70 vs. est. $0.94; sees FY21 revs $530M-$540M vs. est. $541.69M Purple Innovation ($PRPL) Q2 adj EPS $0.05 vs. est. $0.12; Q2 revs $182.6M vs. est. $181.8M; guides year revs $820M-$850M vs. est. $823.6M; sees year Ebitda $78M-$88M vs. est. $81.8M RealReal inc. ($REAL) Q2 EPS loss (-$0.50) vs. est. (-$0.47); Q2 revs $104.91M vs. est. $107.25M; Q2 GMV $350M; said trailing 12 months active buyers reached 730,000, an increase of 19% year-over-year and 48% compared to the same period in 2019; Orders reached 673K, an increase of 53% Y/Y and 33% compared to the same period in 2019. Tesla ($TSLA) sold 32,968 China-made vehicles in July, including 24,347 for export, the China Passenger Car Association (CPCA) said on Tuesday; local sales of China-made vehicles plunged 69% to 8,621 cars from 28,138 in June. Financials First Republic ($FRC) announces offering of 2M shares of common stock CoreCivic ($CXW) Q2 adj FFO $0.46; Q23 revs $464.6M vs. est. $466.1M; Adjusted EBITDA of $101.7M; sale of five non-core real estate assets for gross proceeds of $328.7 million SVB Financial ($SIVB)23M share Spot Secondary priced at $564.00 P. Carey ($WPC) 4.5M share Spot Secondary priced at $78.00 Healthcare BioCryst ($BCRX) announces offering of $200M of common stock, warrants Halozyme ($HALO) Q2 non-GAAP EPS $0.66 vs. est. $0.40; Q2 revs $136.5M vs. est. $103.16M; raises FY21 non-GAAP EPS view to $1.85-$2.00 from $1.55-$1.70 and boosts FY21 revenue view to $425M-$445M from $375M-$395M (est. $404.5M) citing the recent signing of a new collaboration and license agreement and strong year-to-date results Inovio Pharma ($INO) 2Q EPS ($0.39) vs est. ($0.25) on revs $273K; as of June 30, cash and equivalents & s-t investments were $443.7Mm, says continue to evaluate and assess impact of new covid strains Penumbra ($PEN) 2Q adj EPS $0.21 vs est. $0.17 on revs $184.3Mm vs est. $170.8Mm; guides FY revs $720-730Mm vs est. $702.7Mm Reta Pharma ($RETA) 2Q adj EPS ($1.32) vs est. ($2.06); reaffirms cash runway through mid-2024, reaffirms plan to submit MAA with EMA in 4Q21 for marketing approval of bardoxolone for treatment of CKD Rocket Pharma ($RCKT) Q2 EPS loss (-$0.55); expects its balance in cash equivalents and investments of $426.8 mln as of June 30, to fund its operations into 2H 2023 Shockwave Medical ($SWAV) Q2 EPS loss (-$0.01) vs. est. loss (-$0.41); Q2 revs $55.908M vs. est. $45.17M; raises FY21 revenue view $218M-$223M from $195M-$205M (est. $200.6M); Granted approval for a Transitional Pass-Through (TPT) payment for Shockwave C2 Coronary IVL device, which became effective July 1, 2021 for procedures in the outpatient setting SmileDirectClub ($SDC) 2Q EPS ($0.14) vs est. ($0.09) on revs $174Mm vs est. $198.5Mm; guides FY revs $750-800Mm vs est. $833.6Mm; Q2 average aligner gross sales price of $1,885 for Q2, compared to $1,817 for the second quarter of 2020 Steris Plc ($STE) Q1 adj EPS $1.76 vs. est. $1.49; Q1 revs $968.4M vs. est. $904.9M; now expects as reported revenue of approximately $4.6B in 2022, an increase from prior expectations of $4.5B; sees year EPS $7.60-$7.85 vs. est. $7.51; free cash flow for fiscal 2022 is now expected to be approximately $400 mln; raises dividend

134 Replies 14 👍 8 🔥

@TraderXx #StockTraders.NET

Yup $RCKT ladys & Gents! > @TraderXx said: now we can clearly say we are due for a $BPTH type run

66 Replies 6 👍 7 🔥

Key Metrics

Market Cap

1.32 B



Avg. Volume

1.07 M

Shares Outstanding

79.35 M



Public Float


Next Earnings Date


Next Dividend Date

Company Information

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

CEO: Gaurav Shah


HQ: 350 5th Ave Ste 7530 New York, 10118-7501 New York

Related News